Clinical trial Recruiting at 1 site Interventional Ages 75 and up

Huperzine A Injection to reduce postoperative delirium in elderly patients after non-cardiac surgery

Official title: A Multi-center, Randomized, Double-blinded, Placebo-controlled Study of Huperzine A Injection in Reducing Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Surgery

Run by Second Affiliated Hospital of Wenzhou Medical University · NCT05242419 · Data updated 2026-11-12

This study is testing if an injection of Huperzine A can help older patients, aged 75 and up, avoid confusion and delirium after non-heart surgery.

More Non-cardiac Surgery trials

Quick facts

Study typeInterventional
Ages75 Years and up
SexAll
Enrollment40 (estimated)
SponsorSecond Affiliated Hospital of Wenzhou Medical University
Academic / other
Locations1 site (Wenzhou, Zhejiang)
StatusRecruiting
StartedJune 10, 2022
Main results expectedNovember 30, 2025
Study endsDecember 30, 2025
Registry record updatedApril 2, 2025
Trial IDNCT05242419 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are elderly patients aged 75 and older who are scheduled for non-cardiac surgery requiring general anesthesia.

Probably not a fit

Patients with impaired renal or liver function, a history of delirium, or those on psychoactive medications may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of Huperzine A Injection on elderly patients aged 75 and older who are undergoing non-cardiac surgery. The primary focus is to observe whether this intervention can effectively reduce the incidence of postoperative delirium, a common complication in this age group. Patients will receive either Huperzine A or a sodium chloride injection as a control, and their outcomes will be monitored following surgery. The study aims to provide insights into the potential benefits of Huperzine A in improving postoperative recovery for elderly patients.

Why it matters

Potential benefit: If successful, this treatment could significantly reduce the occurrence of postoperative delirium, leading to better recovery outcomes for elderly patients.

How similar studies have gone: While there is limited data on Huperzine A specifically for this purpose, similar studies targeting postoperative delirium in elderly patients have shown promising results with various interventions.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* ≥ 75 years old.
* Comply with the indication of non-cardiac surgery under general anesthesia.
* Anesthesia grade of American Society of Anesthesiologist (ASA) as III\~IV grade.
* The estimated operation time ≥ 2 hours.
* Voluntarily sign the informed consent form.

Exclusion Criteria:

* Patients with impaired renal function (Cr is 1.5 times higher than the upper limit of the normal value of the central laboratory) or abnormal liver function (Alanine aminotransferase(ALT) and Aspartate aminotransferase(AST) are 2 times higher than the upper limit of the normal value of the central laboratory).
* Patients who are positive for infectious diseases.
* Patients accompanied with central nervous system injury.
* Patients with previous history of delirium and epilepsy, long-term use of psychoactive drugs or preoperative assessment of delirium.
* Patients who involved diseases with drug taboos, bronchial asthma, mechanical intestinal obstruction and urinary tract obstruction, or serious systemic diseases, especially circulatory diseases: such as myocardial infarction, heart failure, angina pectoris, history of sinus bradycardia.
* Patients who are known to be allergic to narcotic drugs or Huperzine A Injection, or must use drugs that are not compatible with Huperzine An Injection.
* patients who participated in other clinical trials within 3 months before this study, for any reason, who could not tolerate the test or cooperate with the examination, or who has any aphasia, audio-visual dysfunction, etc.
* the investigators think that the patients is not suitable to participate in this study.

Where it's running

  • The 2nd Second Affiliated Hospital of WMU Phase I Clinical Trial Unit /Center Of Bioequivalence Study
    Wenzhou, Zhejiang, China
    Recruiting

Study contacts

  • Principal investigator: Ting Li, MD. PhD — Second Affiliated Hospital of Wenzhou Medical University
  • Study coordinator: Ting Li, MD. PhD
  • Email: liting1021@aliyun.com
  • Phone: 13587876896

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.